Serum miR-200c expression level as a prognostic biomarker for gastric cancer

Genetics and Molecular Research

Volumn 14, Issue 4, 2015, Pages 15913-15920

  Zhang, H P ^a   Sun, F B ^a   Li, S J ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Gastric cancer; MiR 200c; Prognostic biomarker; Serum

Indexed keywords

MICRORNA 200C; TUMOR MARKER; MICRORNA; MIRN200 MICRORNA, HUMAN;

ADULT; ARTICLE; BLOOD LEVEL; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; OVERALL SURVIVAL; STOMACH CANCER; SURVIVAL RATE; AGED; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH TUMOR;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS;

EID: 84964492022     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.December.7.2     Document Type: Article

References (28)

1. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, et al. (2011). Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad Sci. U. S. A. 108: 5003-5008.
2. Bendoraite A, Knouf EC, Garg KS, Parkin RK, et al. (2010). Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol. Oncol. 116: 117-125.
3. Bertuccio P, Chatenoud L, Levi F, Praud D, et al. (2009). Recent patterns in gastric cancer: a global overview. Int. J. Cancer 125: 666-673.
4. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, et al. (2008). A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68: 7846-7854.
5. Chen X, Ba Y, Ma L, Cai X, et al. (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18: 997-1006.
6. Cortez MA and Calin GA (2009). MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Exp. Opin. Biol. Ther. 9: 703-711.
7. Cortez MA, Welsh JW and Calin GA (2012). Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Res. Cancer Res. 195: 151-161.
8. Cristóbal I, Rincón R, Manso R, Caramés C, et al. (2014). Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis. J. Surg. Oncol. 110: 484-485
9. Deddens JC, Colijn JM, Oerlemans MI, Pasterkamp G, et al. (2013). Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J. Cardiovasc. Transl. Res. 6: 884-898.
10. Esteller M (2011). Non-coding RNAs in human disease. Nat. Rev. Genet. 12: 861-874.
11. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, et al. (2014). Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur. J. Cancer 50: 1330-1344.
12. Gregory PA, Bert AG, Paterson EL, Barry SC, et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10: 593-601.
13. Hayes DF, Isaacs C and Stearns V (2001). Prognostic factors in breast cancer: current and new predictors of metastasis. J. Mamm. Gland Biol. Neoplasia 6: 375-392.
14. Iorio MV, Visone R, Di Leva G, Donati V, et al. (2007). MicroRNA signatures in human ovarian cancer. Cancer Res. 67: 8699-8707.
15. Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M (2012). microRNAs in cancer management. Lancet Oncol. 13: e249-e258.
16. Korpal M, Lee ES, Hu G and Kang Y (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283: 14910-1494.
17. Lee JW, Choi CH, Choi JJ, Park YA, et al. (2008). Altered MicroRNA expression in cervical carcinomas. Clin. Cancer Res. 14: 2535-2542.
18. Liu XG, Zhu WY, Huang YY, Ma LN, et al. (2012). High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. 29: 618-626.
19. Meng F, Henson R, Lang M, Wehbe H, et al. (2006). Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130: 2113-2129.
20. Park SM, Gaur AB, Lengyel E and Peter ME (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22: 894-907.
21. Rutnam ZJ and Yang BB (2012). The involvement of microRNAs in malignant transformation. Histol. Histopathol. 27: 1263-1270.
22. Song F, Yang D, Liu B, Guo Y, et al. (2014). Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin. Cancer Res. 20: 878-889.
23. Tang H, Deng M, Tang Y, Xie X, et al. (2013). miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clin. Cancer Res. 19: 5602-5612.
24. Thery C, Zitvogel L and Amigorena S (2002). Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2: 569-579.
25. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, et al. (2012). Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J. Transl. Med. 10: 186.
26. Yang L (2006). Incidence and mortality of gastric cancer in China. World J. Gastroenterol. 12: 17-20.
27. Zhang GJ, Zhou T, Liu ZL, Tian HP, et al. (2013). Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma. Mol. Clin. Oncol. 1: 3793-3784.
28. Zhang L, Deng T, Li X, Liu H, et al. (2010). microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis 31: 559-566.